Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer

FRIDAY, April 12, 2024 -- Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news